Interacting Drugs |
Ezetimibe and simvastatin vs DAPTOmycin |
Security Level |
 |
Mechanism |
DAPTOmycin: HMG-CoA Reductase Inhibitors may enhance the adverse/toxic effect of DAPTOmycin. Specifically, the risk of skeletal muscle toxicity may be increased. |
Management |
Consider temporarily stopping HMG-CoA reductase inhibitor therapy prior to daptomycin. If used together, regular (i.e., at least weekly) monitoring of CPK concentrations is recommended. |
Ezetimibe and simvastatin vs DAPTOmycin
Post Review about Ezetimibe and simvastatin vs DAPTOmycin Click here to cancel reply.
Other Interactions of DAPTOmycin
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.